Cargando…
D1 MTE2 Case 4: A case of men - 1
Mr. GR, 40 year man presented to us in 2019 with frequent loose stools and generalised tiredness. He has T2DM (7 years, HbA1c-6.7%), CAD (AWMI-PTCA-2013), well-controlled hypertension and his father had primary hyperparathyroidism (all four removed), nephrolithiasis, T2DM, received renal transplant....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067741/ http://dx.doi.org/10.4103/2230-8210.342159 |
_version_ | 1784700072954429440 |
---|---|
author | Dass, Ashwitha Shruti Delampady, Kishan Bhattacharyya, Arpandev |
author_facet | Dass, Ashwitha Shruti Delampady, Kishan Bhattacharyya, Arpandev |
author_sort | Dass, Ashwitha Shruti |
collection | PubMed |
description | Mr. GR, 40 year man presented to us in 2019 with frequent loose stools and generalised tiredness. He has T2DM (7 years, HbA1c-6.7%), CAD (AWMI-PTCA-2013), well-controlled hypertension and his father had primary hyperparathyroidism (all four removed), nephrolithiasis, T2DM, received renal transplant. Five years back, Mr. GR was diagnosed to have Neuroendocrine tumour following distal pancreatectomy and splenectomy on histopathology. Later in 2019, when his scans were repeated for recurrent abdominal symptoms, the new diagnosis of primary hyperparathyroidism was made (PTH-135 [14-65 pg/mL], Corrected Calcium-11.1 [8.5-10.2 mg/dL], Vitamin D-40 [30-40 ng/mL], 24-hour urinary calcium-328 [100-300 mg/day]). Sestamibi scan showed right inferior parathyroid adenoma. He had abdominal issues with elevated Chromogranin A- 6880 (<93 ng/mL) and Gastrin-730 (0-180 pg/mL), Ga 68-DOTATATE scan revealed overexpressing-somatostatin receptor peripancreatic node and pulmonary metastasis. He was started on Octreotide (2 weeks S/C TID following which monthly LAR injection was given for duration of 12 months. His latest reports showed Chromogranin A-325.7, Gastrin-346, Corrected Calcium-11, PTH-136. Presently, he is asymptomatic, improved with no abdominal issues with moderate glycaemic control (HbA1c-6.7%, FBS-121 mg/dl). How would we move forward with the management of this patient? |
format | Online Article Text |
id | pubmed-9067741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-90677412022-05-05 D1 MTE2 Case 4: A case of men - 1 Dass, Ashwitha Shruti Delampady, Kishan Bhattacharyya, Arpandev Indian J Endocrinol Metab Meet the Expert Cases…esicon 2021 Mr. GR, 40 year man presented to us in 2019 with frequent loose stools and generalised tiredness. He has T2DM (7 years, HbA1c-6.7%), CAD (AWMI-PTCA-2013), well-controlled hypertension and his father had primary hyperparathyroidism (all four removed), nephrolithiasis, T2DM, received renal transplant. Five years back, Mr. GR was diagnosed to have Neuroendocrine tumour following distal pancreatectomy and splenectomy on histopathology. Later in 2019, when his scans were repeated for recurrent abdominal symptoms, the new diagnosis of primary hyperparathyroidism was made (PTH-135 [14-65 pg/mL], Corrected Calcium-11.1 [8.5-10.2 mg/dL], Vitamin D-40 [30-40 ng/mL], 24-hour urinary calcium-328 [100-300 mg/day]). Sestamibi scan showed right inferior parathyroid adenoma. He had abdominal issues with elevated Chromogranin A- 6880 (<93 ng/mL) and Gastrin-730 (0-180 pg/mL), Ga 68-DOTATATE scan revealed overexpressing-somatostatin receptor peripancreatic node and pulmonary metastasis. He was started on Octreotide (2 weeks S/C TID following which monthly LAR injection was given for duration of 12 months. His latest reports showed Chromogranin A-325.7, Gastrin-346, Corrected Calcium-11, PTH-136. Presently, he is asymptomatic, improved with no abdominal issues with moderate glycaemic control (HbA1c-6.7%, FBS-121 mg/dl). How would we move forward with the management of this patient? Wolters Kluwer - Medknow 2022-03 /pmc/articles/PMC9067741/ http://dx.doi.org/10.4103/2230-8210.342159 Text en Copyright: © 2022 Indian Journal of Endocrinology and Metabolism https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Meet the Expert Cases…esicon 2021 Dass, Ashwitha Shruti Delampady, Kishan Bhattacharyya, Arpandev D1 MTE2 Case 4: A case of men - 1 |
title | D1 MTE2 Case 4: A case of men - 1 |
title_full | D1 MTE2 Case 4: A case of men - 1 |
title_fullStr | D1 MTE2 Case 4: A case of men - 1 |
title_full_unstemmed | D1 MTE2 Case 4: A case of men - 1 |
title_short | D1 MTE2 Case 4: A case of men - 1 |
title_sort | d1 mte2 case 4: a case of men - 1 |
topic | Meet the Expert Cases…esicon 2021 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067741/ http://dx.doi.org/10.4103/2230-8210.342159 |
work_keys_str_mv | AT dassashwithashruti d1mte2case4acaseofmen1 AT delampadykishan d1mte2case4acaseofmen1 AT bhattacharyyaarpandev d1mte2case4acaseofmen1 |